- SalvaRx Group Plc is a Isle of Man-based company. The Company engaged in drug discovery and development, focused on immune oncology. The Company invests in novel cancer immuno-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Delayed London S.E.			5-day change	1st Jan Change
- ^GBX	-.--%		-47.06%	-

26/09/19	SalvaRx Evaluates Takeover Opportunities	CI
26/09/19	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI

Market Cap	1.65M 1.48M 1.35M 1.24M 2.33M 155M 2.4M 16.32M 6.51M 82.83M 6.2M 6.07M 262M	P/E 2017	-4.13x	P/E 2018	83x
Enterprise Value	2.41M 2.17M 1.98M 1.81M 3.4M 227M 3.51M 23.86M 9.51M 121M 9.06M 8.87M 382M	EV / Sales 2017	-	EV / Sales 2018	-
Free-Float	20.33%	Yield 2017 *	-	Yield 2018	-

26/09/19	SalvaRx Evaluates Takeover Opportunities	CI
26/09/19	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI
28/06/19	Salvarx Group plc Reports Earnings Results for the Full Year Ended December 31, 2018	CI
08/01/19	Portage Biotech Inc. (OTCPK:PTGE.F) completed the acquisition of SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile.	CI
27/09/18	SalvaRx Group plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018	CI
14/08/18	Portage Biotech Inc. (OTCPK:PTGE.F) (‘Portage’) entered into a conditional sale agreement to acquire SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile for $80.5 million.	CI
28/06/18	SalvaRx Group plc Announces Consolidated Earnings Results for the Year Ended December 31, 2017	CI
28/06/18	SalvaRx Seeks Acquisitions	CI
26/06/18	SalvaRx Announces an Unsecured $1 Million Loan	CI
27/09/17	SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017	CI
30/06/17	SalvaRx Group plc Announces Final Audited Consolidated Earnings Results for the Year Ended December 31, 2016	CI
30/06/17	SalvaRx Seeks Investments	CI
30/05/17	SalvaRx Group plc Treats First Patient INT230-6 as Part of A Phase 1/2 International Clinical Study	CI

14/10/20	SalvaRx : Portage Issues Common Shares and Warrants in Settlement of SalvaRx Loan Note Obligations	AQ
27/09/19	SalvaRx : Half Yearly Report 30 June 2019 RNS	PU
26/09/19	SalvaRx : RNS SalvaRx Group PLC interim report 30 June 2019	PU

SalvaRx Group plc Stock

Stocks

SALV

IM00BZ4SS228

Biotechnology & Medical Research

Valuation: SalvaRx Group plc

Latest news: SalvaRx Group plc

Press Releases: SalvaRx Group plc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SALVARX GROUP PLC	-.--%	-47.06%	-	-	2.16M
WUXI APPTEC CO., LTD.	-4.83%	+2.88%	+55.87%	+69.12%	69.4B
ARGENX SE	+0.02%	+1.07%	+10.63%	+76.66%	57.24B
LONZA GROUP AG	-1.34%	+2.98%	+24.79%	+100.18%	57.62B
IQVIA HOLDINGS INC.	+2.44%	+1.45%	+28.62%	+36.69%	43.65B
BEONE MEDICINES AG	+5.60%	+10.67%	+23.32%	+108.96%	44.03B
REVOLUTION MEDICINES, INC.	+8.53%	+0.57%	+213.45%	+793.20%	38.08B
CELLTRION, INC.	-1.86%	+11.46%	+26.67%	+61.40%	36.31B
GENMAB A/S	-2.97%	-9.84%	+88.86%	+76.17%	32.61B
WUXI BIOLOGICS (CAYMAN) INC.	-2.18%	+5.68%	+36.21%	-0.69%	25.47B
Average	+0.36%	-2.69%	+56.49%	+146.86%	40.44B
Weighted average by Cap.	+0.14%	+2.44%	+52.19%	+139.10%

	2017	2018
Net sales	-	-
Net income	-1.74M -1.56M -1.43M -1.3M -2.46M -164M -2.54M -17.23M -6.87M -87.48M -6.55M -6.41M -276M	342K 307K 280K 256K 482K 32.15M 497K 3.38M 1.35M 17.15M 1.28M 1.26M 54.15M
Net Debt	2.22M 1.99M 1.82M 1.66M 3.13M 209M 3.23M 21.95M 8.75M 111M 8.34M 8.16M 352M	763K 684K 625K 571K 1.08M 71.72M 1.11M 7.54M 3.01M 38.27M 2.86M 2.8M 121M